"Discover High-Growth Opportunities Across Leading Sectors, With BCC Research Highlighting Industries Primed for Up to 20% Annual Returns" BOSTON, Oct. 30, 2024 /PRNewswire/ -- CAGR offers ...

Amplia Therapeutics Ltd. (AU:ATX) has released an update. Amplia Therapeutics Ltd. announces its plan to issue up to 5,433,750 new securities ...

PYC Therapeutics Limited (AU:PYC) has released an update. PYC Therapeutics, a clinical-stage biotech firm focused on RNA therapies, is poised ...

Spark Therapeutics’s Luxturna (voretigene neparvovec) made history in December when it became the first FDA-approved gene therapy, licensed to treat patients with a rare genetic form of blindness.

Live webcasts of the presentations will be available via the Events & Presentations page in the Investors section of ADC Therapeutics' website, ir.adctherapeutics.com. A replay of each webcast ...

CAGR offers a clear view of long-term investment trends by balancing fluctuations for a steady growth rate. BCC Research ...

Spark Therapeutics is on the cusp of gaining the first ever approval for a gene therapy from the FDA, a groundbreaking treatment which restores vision to children and adults with a rare inherited ...

Chief Medical Officer of ADC Therapeutics. "All complete metabolic responses were maintained, with 4 of the 10 partial metabolic responses improving at week 21 for a best complete metabolic ...

Spark Therapeutics: Spark Therapeutics, a leading gene therapy company, utilizes viral vectors to develop treatments for inherited diseases. Their technology employs adeno-associated virus (AAV ...

Live webcasts of the presentations will be available via the Events & Presentations page in the Investors section of ADC Therapeutics' website, ir.adctherapeutics.com. A replay of each webcast will be ...